查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1905553

日本糖尿病药物市场报告（按类型（胰岛素、口服降血糖药、非胰岛素注射剂、复方製剂）、配销通路（线上药局、医院药局、零售药局）及地区划分，2026-2034年）

Japan Diabetes Drugs Market Report by Type (Insulins, Oral Anti-diabetic Drugs, Non-Insulin Injectable Drugs, Combination Drugs), Distribution Channel (Online Pharmacies, Hospital Pharmacies Retail Pharmacies), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 117 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2025年，日本糖尿病药物市场规模达46亿美元。展望未来， IMARC Group预计到2034年，该市场规模将达到61亿美元，2026年至2034年间的复合年增长率（CAGR）为3.33%。推动市场成长的主要因素是，越来越多成熟的製药公司致力于研发、生产和销售各种糖尿病药物，旨在有效控制血糖水平。

本报告解答的关键问题：

  • 日本糖尿病药物市场目前表现如何？未来几年又将如何发展？
  • 新冠疫情对日本糖尿病药物市场产生了哪些影响？
  • 日本糖尿病药物市场按类型分類的组成是怎样的？
  • 日本糖尿病药物市场按配销通路分類的组成是怎样的？
  • 日本糖尿病药物市场价值链的各个阶段有哪些？
  • 日本糖尿病药物的关键驱动因素和挑战是什么？
  • 日本糖尿病药物市场的结构是怎么样的？主要参与者有哪些？
  • 日本糖尿病药物市场的竞争程度如何？

目录

第一章：序言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 数据来源
  • 市场估算
  • 预测方法

第三章：执行概要

第四章：日本糖尿病药物市场－简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本糖尿病药物市场概况

  • 历史及当前市场趋势（2020-2025）
  • 市场预测（2026-2034）

第六章：日本糖尿病药物市场－按类型划分

  • 胰岛素
  • 口服抗糖尿病药物
  • 非胰岛素注射药物
  • 复方药物

第七章：日本糖尿病药物市场－依配销通路划分

  • 网路药局
  • 医院药房
  • 零售药局

第八章：日本糖尿病药物市场－按地区划分

  • 关东地区
  • 关西/近畿地区
  • 中部/中部地区
  • 九州·冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

第九章：日本糖尿病药物市场－竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳制胜策略
  • 竞争格局分析
  • 公司评估象限

第十章：关键参与者简介

第十一章：日本糖尿病药物市场－产业分析

  • 驱动因素、限制因素和机会
  • 波特五力分析
  • 价值链分析

第十二章：附录

简介目录
Product Code: SR112026A15502

Japan diabetes drugs market size reached USD 4.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 6.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.33% during 2026-2034. The rising number of established pharmaceutical companies engaged in the development, production, and distribution of a diverse range of diabetes medications, each aiming to control blood glucose levels effectively is primarily driving the market growth

Diabetes drugs play a pivotal role in managing and treating diabetes, a chronic condition characterized by elevated blood sugar levels due to the body's inability to produce sufficient insulin or utilize it effectively. These pharmaceutical agents are crucial in controlling the progression of the disease and mitigating the risk of complications, such as cardiovascular disease, kidney damage, and vision loss. There are various classes of diabetes drugs, each working differently to regulate blood glucose levels. Some are designed to boost insulin secretion, while others improve insulin sensitivity or decrease the amount of glucose absorbed by the intestines.

Japan Diabetes Drugs Market Trends:

The Japan diabetes drugs market is a rapidly evolving sector, responding to the escalating need stemming from the widespread prevalence of diabetes in the region, predominantly influenced by aging demographics and lifestyle alterations. The dynamics of this market are shaped by the infusion of innovative solutions and relentless research endeavors by prominent pharmaceutical entities, aimed at devising diverse medication strategies to meticulously regulate blood glucose levels. The market is experiencing substantial growth, fueled by a heightened awareness and understanding of diabetes and its associated complications. The propensity towards embracing novel and effective diabetes medications is prominent in Japan, with a significant inclination towards the integration of advanced drugs, such as GLP-1 receptor agonists, which are gaining traction due to their efficacy and multifunctionality in managing blood sugar levels and weight. A distinctive trend in the market is the burgeoning investment in R&D activities, fostering the development of groundbreaking drugs with enhanced capabilities and reduced side effects. The advent of personalized medicine is also playing a pivotal role in shaping the market landscape, enabling more tailored and patient-centric approaches to treatment. The heightened emphasis on healthcare and wellness, coupled with supportive regulatory frameworks and substantial healthcare expenditure, is anticipated to propel the regional market forward over the forecasted period.

Japan Diabetes Drugs Market Segmentation:

Type Insights:

  • Insulins
    • Basal or Long Acting Insulins
  • Lantus (Insulin Glargine)
  • Levemir (Insulin Detemir)
  • Toujeo (Insulin Glargine)
  • Tresiba (Insulin Degludec)
  • Basaglar (Insulin Glargine)
    • Bolus or Fast Acting Insulins
  • NovoRapid/Novolog (Insulin Aspart)
  • Humalog (Insulin Lispro)
  • Apidra (Insulin Glulisine)
    • Traditional Human Insulins
  • Novolin/Actrapid/Insulatard
  • Humulin
  • Insuman
    • Biosimilar Insulins
  • Insulin Glargine Biosimilars
  • Human Insulin Biosimilars
  • Oral Anti-diabetic Drugs
    • Biguanides
  • Metformin
    • Alpha-Glucosidase Inhibitors
    • Dopamine D2 Receptor Agonist
  • Bromocriptin
    • SGLT-2 Inhibitor
  • Invokana (Canagliflozin)
  • Jardiance (Empagliflozin)
  • Farxiga/Forxiga (Dapagliflozin)
  • Suglat (Ipragliflozin)
    • DPP-4 Inhibitors
  • Onglyza (Saxagliptin)
  • Tradjenta (Linagliptin)
  • Vipidia/Nesina (Alogliptin)
  • Galvus (Vildagliptin)
    • Sulfonylureas
    • Meglitinides
  • Non-Insulin Injectable Drugs
    • GLP-1 Receptor Agonists
  • Victoza (Liraglutide)
  • Byetta (Exenatide)
  • Bydureon (Exenatide)
  • Trulicity (Dulaglutide)
  • Lyxumia (Lixisenatide)
    • Amylin Analogue
  • Symlin (Pramlintide)
  • Combination Drugs
    • Insulin Combinations
  • NovoMix (Biphasic Insulin Aspart)
  • Ryzodeg (Insulin Degludec and Insulin Aspart)
  • Xultophy (Insulin Degludec and Liraglutide)
    • Oral Combination
  • Janumet (Sitagliptin and Metformin)

Distribution Channel Insights:

  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region
  • The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan diabetes drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan diabetes drugs market?
  • What is the breakup of the Japan diabetes drugs market on the basis of type?
  • What is the breakup of the Japan diabetes drugs market on the basis of distribution channel?
  • What are the various stages in the value chain of the Japan diabetes drugs market?
  • What are the key driving factors and challenges in the Japan diabetes drugs?
  • What is the structure of the Japan diabetes drugs market and who are the key players?
  • What is the degree of competition in the Japan diabetes drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Diabetes Drugs Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Diabetes Drugs Market Landscape

  • 5.1 Historical and Current Market Trends (2020-2025)
  • 5.2 Market Forecast (2026-2034)

6 Japan Diabetes Drugs Market - Breakup by Type

  • 6.1 Insulins
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2020-2025)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Basal or Long Acting Insulins
        • 6.1.3.1.1 Lantus (Insulin Glargine)
        • 6.1.3.1.2 Levemir (Insulin Detemir)
        • 6.1.3.1.3 Toujeo (Insulin Glargine)
        • 6.1.3.1.4 Tresiba (Insulin Degludec)
        • 6.1.3.1.5 Basaglar (Insulin Glargine)
      • 6.1.3.2 Bolus or Fast Acting Insulins
        • 6.1.3.2.1 NovoRapid/Novolog (Insulin Aspart)
        • 6.1.3.2.2 Humalog (Insulin Lispro)
        • 6.1.3.2.3 Apidra (Insulin Glulisine)
      • 6.1.3.3 Traditional Human Insulins
        • 6.1.3.3.1 Novolin/Actrapid/Insulatard
        • 6.1.3.3.2 Humulin
        • 6.1.3.3.3 Insuman
      • 6.1.3.4 Biosimilar Insulins
        • 6.1.3.4.1 Insulin Glargine Biosimilars
        • 6.1.3.4.2 Human Insulin Biosimilars
    • 6.1.4 Market Forecast (2026-2034)
  • 6.2 Oral Anti-diabetic Drugs
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2020-2025)
    • 6.2.3 Market Segmentation
      • 6.2.3.1 Biguanides
        • 6.2.3.1.1 Metformin
      • 6.2.3.2 Alpha-Glucosidase Inhibitors
      • 6.2.3.3 Dopamine D2 Receptor Agonist
        • 6.2.3.3.1 Bromocriptin
      • 6.2.3.4 SGLT-2 Inhibitors
        • 6.2.3.4.1 Invokana (Canagliflozin)
        • 6.2.3.4.2 Jardiance (Empagliflozin)
        • 6.2.3.4.3 Farxiga/Forxiga (Dapagliflozin)
        • 6.2.3.4.4 Suglat (Ipragliflozin)
      • 6.2.3.5 DPP-4 Inhibitors
        • 6.2.3.5.1 Onglyza (Saxagliptin)
        • 6.2.3.5.2 Tradjenta (Linagliptin)
        • 6.2.3.5.3 Vipidia/Nesina (Alogliptin)
        • 6.2.3.5.4 Galvus (Vildagliptin)
      • 6.2.3.6 Sulfonylureas
      • 6.2.3.7 Meglitinides
    • 6.2.4 Market Forecast (2026-2034)
  • 6.3 Non-Insulin Injectable Drugs
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2020-2025)
    • 6.3.3 Market Segmentation
      • 6.3.3.1 GLP-1 Receptor Agonists
        • 6.3.3.1.1 Victoza (Liraglutide)
        • 6.3.3.1.2 Byetta (Exenatide)
        • 6.3.3.1.3 Bydureon (Exenatide)
        • 6.3.3.1.4 Trulicity (Dulaglutide)
        • 6.3.3.1.5 Lyxumia (Lixisenatide)
      • 6.3.3.2 Amylin Analogue
        • 6.3.3.2.1 Symlin (Pramlintide)
    • 6.3.4 Market Forecast (2026-2034)
  • 6.4 Combination Drugs
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2020-2025)
    • 6.1.2 Market Segmentation
      • 6.3.3.1 Insulin Combinations
        • 6.3.3.1.1 NovoMix (Biphasic Insulin Aspart)
        • 6.3.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
        • 6.3.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
      • 6.3.3.2 Oral Combinations
        • 6.3.3.2.1 Janumet (Sitagliptin and Metformin)
    • 6.4.4 Market Forecast (2026-2034)

7 Japan Diabetes Drugs Market - Breakup by Distribution Channel

  • 7.1 Online Pharmacies
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2020-2025)
    • 7.1.3 Market Forecast (2026-2034)
  • 7.2 Hospital Pharmacies
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2020-2025)
    • 7.2.3 Market Forecast (2026-2034)
  • 7.3 Retail Pharmacies
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2020-2025)
    • 7.3.3 Market Forecast (2026-2034)

8 Japan Diabetes Drugs Market - Breakup by Region

  • 8.1 Kanto Region
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2020-2025)
    • 8.1.3 Market Breakup by Type
    • 8.1.4 Market Breakup by Distribution Channel
    • 8.1.5 Key Players
    • 8.1.6 Market Forecast (2026-2034)
  • 8.2 Kansai/Kinki Region
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2020-2025)
    • 8.2.3 Market Breakup by Type
    • 8.2.4 Market Breakup by Distribution Channel
    • 8.2.5 Key Players
    • 8.2.6 Market Forecast (2026-2034)
  • 8.3 Central/ Chubu Region
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2020-2025)
    • 8.3.3 Market Breakup by Type
    • 8.3.4 Market Breakup by Distribution Channel
    • 8.3.5 Key Players
    • 8.3.6 Market Forecast (2026-2034)
  • 8.4 Kyushu-Okinawa Region
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2020-2025)
    • 8.4.3 Market Breakup by Type
    • 8.4.4 Market Breakup by Distribution Channel
    • 8.4.5 Key Players
    • 8.4.6 Market Forecast (2026-2034)
  • 8.5 Tohoku Region
    • 8.5.1 Overview
    • 8.5.2 Historical and Current Market Trends (2020-2025)
    • 8.5.3 Market Breakup by Type
    • 8.5.4 Market Breakup by Distribution Channel
    • 8.5.5 Key Players
    • 8.5.6 Market Forecast (2026-2034)
  • 8.6 Chugoku Region
    • 8.6.1 Overview
    • 8.6.2 Historical and Current Market Trends (2020-2025)
    • 8.6.3 Market Breakup by Type
    • 8.6.4 Market Breakup by Distribution Channel
    • 8.6.5 Key Players
    • 8.6.6 Market Forecast (2026-2034)
  • 8.7 Hokkaido Region
    • 8.7.1 Overview
    • 8.7.2 Historical and Current Market Trends (2020-2025)
    • 8.7.3 Market Breakup by Type
    • 8.7.4 Market Breakup by Distribution Channel
    • 8.7.5 Key Players
    • 8.7.6 Market Forecast (2026-2034)
  • 8.8 Shikoku Region
    • 8.8.1 Overview
    • 8.8.2 Historical and Current Market Trends (2020-2025)
    • 8.8.3 Market Breakup by Type
    • 8.8.4 Market Breakup by Distribution Channel
    • 8.8.5 Key Players
    • 8.8.6 Market Forecast (2026-2034)

9 Japan Diabetes Drugs Market - Competitive Landscape

  • 9.1 Overview
  • 9.2 Market Structure
  • 9.3 Market Player Positioning
  • 9.4 Top Winning Strategies
  • 9.5 Competitive Dashboard
  • 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

  • 10.1 Company A
    • 10.1.1 Business Overview
    • 10.1.2 Product Portfolio
    • 10.1.3 Business Strategies
    • 10.1.4 SWOT Analysis
    • 10.1.5 Major News and Events
  • 10.2 Company B
    • 10.2.1 Business Overview
    • 10.2.2 Product Portfolio
    • 10.2.3 Business Strategies
    • 10.2.4 SWOT Analysis
    • 10.2.5 Major News and Events
  • 10.3 Company C
    • 10.3.1 Business Overview
    • 10.3.2 Product Portfolio
    • 10.3.3 Business Strategies
    • 10.3.4 SWOT Analysis
    • 10.3.5 Major News and Events
  • 10.4 Company D
    • 10.4.1 Business Overview
    • 10.4.2 Product Portfolio
    • 10.4.3 Business Strategies
    • 10.4.4 SWOT Analysis
    • 10.4.5 Major News and Events
  • 10.5 Company E
    • 10.5.1 Business Overview
    • 10.5.2 Product Portfolio
    • 10.5.3 Business Strategies
    • 10.5.4 SWOT Analysis
    • 10.5.5 Major News and Events

11 Japan Diabetes Drugs Market - Industry Analysis

  • 11.1 Drivers, Restraints, and Opportunities
    • 11.1.1 Overview
    • 11.1.2 Drivers
    • 11.1.3 Restraints
    • 11.1.4 Opportunities
  • 11.2 Porters Five Forces Analysis
    • 11.2.1 Overview
    • 11.2.2 Bargaining Power of Buyers
    • 11.2.3 Bargaining Power of Suppliers
    • 11.2.4 Degree of Competition
    • 11.2.5 Threat of New Entrants
    • 11.2.6 Threat of Substitutes
  • 11.3 Value Chain Analysis

12 Appendix